A surprising number of common medications can trigger a false positive for benzodiazepines on a standard urine drug screen. The culprits range from a widely prescribed antidepressant to an over-the-counter anti-inflammatory, and even an HIV medication. These errors happen because the initial screening tests used in most clinical and workplace settings rely on antibody-based detection methods that can mistake structurally similar molecules for benzodiazepines. Understanding which substances cause these mix-ups, and how the testing process is supposed to catch them, matters for anyone whose prescription medications might put them at risk of a wrongly flagged result.
How Screening Tests Get Tripped Up
Most urine drug screens start with an immunoassay, a rapid, inexpensive test that uses antibodies designed to bind to benzodiazepines or their breakdown products. The problem is that these antibodies are not perfectly selective. They can latch onto other molecules that share a similar shape or chemical structure, producing a positive signal even when no actual benzodiazepine is present. This phenomenon is called cross-reactivity, and it affects screening tests for nearly every drug class, not just benzodiazepines.
A comprehensive review covering the literature from 2000 onward found that false-positive interferences were described for benzodiazepines alongside several other drug classes, including amphetamines, opiates, and cannabinoids.1Oxford Academic (Journal of Analytical Toxicology). False-positive interferences of common urine drug screen immunoassays: a review The takeaway is that a positive immunoassay result is a starting point, not a verdict. Confirmatory testing with a more precise method is needed to tell whether the flagged substance is truly present.
Sertraline, the Antidepressant That Fools Benzo Tests
Sertraline (sold as Zoloft) is one of the most commonly prescribed antidepressants and one of the best-documented causes of false-positive benzodiazepine screens. A retrospective review of 522 drug test records found 160 results later confirmed as false positives. Among the 98 false positives not explained by an actual benzodiazepine prescription, 26 were linked to patients taking sertraline.2PubMed Central. False-Positive Urine Screening for Benzodiazepines: An Association with Sertraline?: A Two-year Retrospective Chart Analysis That is a substantial proportion from a single medication.
The issue traces to the way sertraline and its metabolites interact with specific immunoassay platforms. Early versions of one widely used assay, the CEDIA benzodiazepine test, cross-reacted with sertraline. The manufacturer eventually developed an improved version specifically to eliminate this cross-reactivity.3Journal of Analytical Toxicology. Improved CEDIA® Benzodiazepine Assay Eliminates Sertraline Crossreactivity Newer assay formulations have reduced the problem, but older or less frequently updated testing platforms may still be vulnerable. If you take sertraline and face regular drug screening, this is worth raising with whoever orders or interprets your tests.
Oxaprozin, an Overlooked Anti-Inflammatory
Oxaprozin (brand name Daypro) is a nonsteroidal anti-inflammatory drug prescribed for arthritis and joint pain. It has been shown to cross-react for benzodiazepines in several different immunoassay methods, meaning a patient taking it for knee or hip pain could test positive on a routine drug screen without having taken any benzodiazepine.4Journal of Analytical Toxicology. Oxaprozin Cross-Reactivity in Three Commercial Immunoassays for Benzodiazepines in Urine
What makes oxaprozin particularly tricky is that it is a straightforward pain reliever. People do not typically think of an anti-inflammatory as something that could cause a positive drug test. Unlike ibuprofen or naproxen, which are the more commonly used NSAIDs and do not trigger benzo screens, oxaprozin’s molecular structure is different enough to fool the antibodies. If you are prescribed oxaprozin and undergo drug testing for work, pain management, or any other reason, disclosing the medication ahead of time can save a lot of unnecessary worry.
Efavirenz, an HIV Medication with Near-Universal Cross-Reactivity
One of the most dramatic examples comes from efavirenz, an antiretroviral drug used in HIV treatment. In a study of 100 HIV-positive patients, 49 of the 50 patients receiving efavirenz tested positive for benzodiazepines on at least one drug screening test. Among the 50 patients not taking efavirenz, only one tested positive.5PubMed. Efavirenz treatment and false-positive results in benzodiazepine screening tests The cross-reactivity was traced to 8-hydroxy-efavirenz, a major metabolite of the drug.
Those numbers are striking: a 98% false-positive rate among efavirenz users. Although efavirenz has become less commonly prescribed as newer HIV regimens have emerged, it remains in use in some settings, particularly in resource-limited healthcare systems. Anyone taking efavirenz who is subject to drug testing should be aware that a false-positive benzodiazepine result is essentially expected, not an anomaly.
Other Psychiatric and Neurological Medications
The list of medications linked to false-positive drug screens extends well beyond sertraline. A literature review in a psychiatric journal documented false-positive drug test results associated with a wide range of psychotropic medications, including other antidepressants like trazodone, antihistamines like hydroxyzine, antipsychotics such as quetiapine and haloperidol, and mood stabilizers like carbamazepine and lamotrigine.6Psychiatria Polska. False-positive drug test results in patients taking psychotropic drugs. A literature review Not all of these drugs specifically cause false-positive benzodiazepine results; some interfere with other drug class assays such as amphetamine or tricyclic antidepressant screens. But the broader point is that psychiatric patients are disproportionately affected by false positives because they take the very medications most likely to cross-react.
This creates a real clinical and social problem. A patient in a substance abuse recovery program, for example, might be taking quetiapine for sleep or mood stabilization and then face consequences for a positive benzodiazepine screen they did not earn. Similarly, people on anti-seizure medications like carbamazepine might get flagged in workplace testing. The burden often falls on the patient to prove the result is wrong, which is why disclosure of all current medications to the testing provider is important.
Herbal Supplements with Hidden Ingredients
Sometimes a positive benzodiazepine screen is not a false positive at all in the chemical sense, but the person genuinely has no idea they ingested a benzodiazepine. This happens with adulterated supplements. A documented case involved a female athlete who tested positive for benzodiazepines on a random drug screen and denied taking any prescription or illicit drugs. The positive result turned out to be caused by undeclared diazepam added to a Chinese herbal product marketed as “Miracle Herb.”7PubMed Central. Positive drug screen for benzodiazepine due to a chinese herbal product
This is a different problem from immunoassay cross-reactivity. The test correctly detected a benzodiazepine because a benzodiazepine was actually in the product. Some foreign-manufactured vitamins, herbal teas, and health supplements contain banned or undisclosed ingredients, including benzodiazepines, corticosteroids, and other pharmaceutical compounds. If you use herbal or imported supplements and are subject to drug testing, this is a risk that no amount of medication disclosure can address, because you may not know what is actually in the product.
Why the Specific Test Platform Matters
Not all immunoassays perform the same way, even when they are screening for the same drug class. Different manufacturers use different antibodies, different detection methods, and different cutoff concentrations. These variations lead to meaningfully different rates of false positives and false negatives.
A head-to-head comparison of two common immunoassay platforms found that the CEDIA method produced 7 false positives and no false negatives, while the EMIT II method produced just 1 false positive but 13 false negatives.8Clinica Chimica Acta. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines In other words, the more sensitive assay catches more true positives but also produces more false alarms. A broader evaluation across multiple assay platforms found similar trade-offs, with KIMS II and CEDIA immunoassays generally showing higher reactivity than EMIT II Plus.9Drug Testing and Analysis. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
A national proficiency test across 178 laboratories in Italy found that specificity was compromised by high false-positive rates across all immunoassay platforms tested, and the assays tended to overestimate the amount of benzodiazepines present.10Journal of Analytical Toxicology. Comparison of Immunoassay Screening Tests and LC–MS-MS for Urine Detection of Benzodiazepines and Their Metabolites: Results of a National Proficiency Test The practical implication is that two labs running the same urine sample on different equipment could get different results, and the person being tested has no control over which platform is used.
Point-of-Care Tests vs. Laboratory Testing
The setting where your test is performed also affects accuracy. Point-of-care testing devices, including the cup-based rapid tests used in many emergency departments, urgent care clinics, and workplace screening programs, may be less reliable than laboratory-based immunoassays run on automated analyzers. Research has found that these rapid devices can produce higher rates of false positives compared to laboratory instruments.11Critical Issues in Alcohol and Drugs of Abuse Testing. Point of Care Devices for Drugs of Abuse Testing: Limitations and Pitfalls
This matters because point-of-care results sometimes carry immediate consequences. An emergency room physician might make treatment decisions based on a rapid screen, or a workplace testing program might initiate disciplinary action before confirmatory testing is complete. The convenience and speed of point-of-care devices come with an accuracy trade-off that is not always well communicated to the person being tested.
Designer Benzodiazepines and “False” Positives That Are Not Quite False
There is a complicating wrinkle in the false-positive conversation that has grown more relevant in recent years. Designer benzodiazepines, which are synthetic compounds not approved by the FDA but pharmacologically similar to prescription benzodiazepines, can trigger a positive immunoassay screen. When the laboratory then runs confirmatory testing using a standard panel that only looks for common prescription benzodiazepines, it finds nothing, and the result gets labeled a false positive.
A study of 35 emergency department patients whose benzodiazepine screens appeared to be false positives found that the immunoassays were actually cross-reacting with non-FDA-approved designer benzodiazepines that the standard confirmatory panel was not designed to detect.12Journal of Analytical Toxicology. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC–QTOF-MS and LC–MS-MS In these cases, the screening test was doing its job: it detected a benzodiazepine-like substance. The problem was that the confirmatory test was too narrow to identify which one. This means some results classified as false positives are actually true positives for substances the lab was not looking for, which complicates both clinical care and forensic interpretation.
Unusual Biological Interferents
Beyond medications and supplements, certain biological conditions in the sample itself can cause false-positive results. Research on postmortem urine specimens found that the presence of lactate dehydrogenase and lactic acid, along with elevated protein levels, produced false-positive reactions on immunoassay drug screens.13PubMed. False-positive postmortem EMIT drugs-of-abuse assay due to lactate dehydrogenase and lactate in urine While this phenomenon was documented in postmortem samples, where enzyme levels and sample integrity differ substantially from living patients, it illustrates that the sample’s composition, not just what drugs a person has taken, can influence results. Severely degraded or improperly stored specimens might be more prone to this kind of interference, though it is not a common concern for routine clinical or workplace testing.
How Confirmatory Testing Works
The standard practice when an immunoassay comes back positive is to confirm the result using a more precise analytical method, typically liquid chromatography-tandem mass spectrometry (LC-MS-MS) or gas chromatography-mass spectrometry (GC-MS). These techniques identify specific molecules by their exact chemical fingerprint rather than relying on antibody binding, which effectively eliminates cross-reactivity as a source of error.
One technical nuance that affects confirmatory testing is whether the laboratory hydrolyzes the sample before analysis. Many benzodiazepines are excreted in urine as glucuronide conjugates, meaning they are chemically linked to a sugar molecule. If the lab does not break that bond before testing, it may undercount the actual drug present. Studies have shown that using a hydrolysis step before analysis substantially increases the detection of specific benzodiazepines like oxazepam, lorazepam, and temazepam, with some enzyme preparations achieving recovery rates above 94% for oxazepam and lorazepam.14The Journal of Applied Laboratory Medicine. Opiate & Benzodiazepine Confirmations: To Hydrolyze or Not to Hydrolyze is the Question
This mostly matters for avoiding false negatives rather than false positives, but it is part of the broader picture of how confirmatory test methodology affects the final answer a patient receives. A lab that skips hydrolysis might fail to confirm a true positive, while a lab that performs it might correctly identify a drug that the immunoassay also detected. The overall reliability of the testing process depends on both the screening step and the confirmation step being performed well.
What You Can Do About It
If you are taking any medication and know you will be drug tested, the single most protective step is to provide a complete list of all prescription and over-the-counter medications, including supplements, to the medical review officer or testing provider before the test. This does not guarantee that a false positive will not occur, but it gives the person interpreting the result a plausible explanation and a reason to order confirmatory testing.
If you receive a positive result you believe is wrong, request confirmatory testing by GC-MS or LC-MS-MS. In many regulated testing programs, such as federal workplace drug testing in the United States, confirmatory testing is already mandatory before any action is taken on a positive screen. But in clinical settings like emergency departments or pain management clinics, the initial immunoassay result sometimes gets treated as definitive, and patients may need to advocate for confirmation themselves.
It also helps to know which of your medications are on the list of known cross-reactants. The medications most consistently linked to false-positive benzodiazepine screens in the literature include sertraline, oxaprozin, and efavirenz. If you take any of these and face drug testing, a conversation with your prescribing physician about documentation can prevent a positive screen from becoming a much bigger problem than it needs to be.
The Evolving Landscape of Drug Screen Interference
New medications enter the market regularly, and the immunoassay platforms used for drug screening are updated on their own timelines. This means the list of substances known to cause false-positive benzodiazepine results is not static. A review covering studies published between 2013 and 2024 identified 61 studies meeting inclusion criteria from 569 publications, each documenting interferences across commonly screened drug classes including benzodiazepines.15Oxford Academic (Journal of Analytical Toxicology). False positive urine drug screens The ongoing pace of new reports suggests that cross-reactivity is not a problem that has been solved; it is one that gets incrementally better as assays improve but never fully disappears. New drugs, new metabolites, and new assay formulations keep reshuffling the deck. For patients and clinicians alike, treating any positive immunoassay screen as preliminary rather than conclusive remains the safest approach.